Applicability of chest echography and procalcitonin pulmonary infection score(CEPPIS) in patients with ventilator-associated pneumonia(VAP)

ZHU Qian; DU Juan; HUANG Xiaoying; WEN Dalin; LUO Li; PENG Xiaoyu; GAN Ping; TANG Hao

PDF(688 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2020, Vol. 31 ›› Issue (8) : 649-653.

Applicability of chest echography and procalcitonin pulmonary infection score(CEPPIS) in patients with ventilator-associated pneumonia(VAP)

ZHU Qian¹, DU Juan², HUANG Xiaoying², WEN Dalin², LUO Li², PENG Xiaoyu², GAN Ping¹, TANG Hao²

Author information +

History +

Abstract

Objective To evaluate the diagnostic performance of the chest echography and procalcitonin pulmonary infection score(CEPPIS) of patients with ventilator-associated pneumonia(VAP).Methods Patients who were on mechanical ventilation in the intensive care unit (ICU) of Army Medical Center and met the inclusion criteria were included in this study. These patients were divided into the VAP group and control group according to the culture results of bronchial microorganisms (with nosocomial infection and total bacterial colonies>10⁵/ml). Demographic information, clinical features and prognosis were compared via statistical analysis. The CEPPIS and clinical pulmonary infection score(CPIS) were graded using indicators including pulmonary echography, bedside chest radiography, procalcitonin and sputum culture when patients experienced dyspnea or decreased oxygenation. A receiver operating characteristic (ROC) analysis was conducted of CEPPIS, CPIS and procalcitonin to evaluate their diagnostic performance.Results A total of 144 patients were included with 71 patients in the VAP group and 73 in the control group. 93(64.6%) of them were males, and the average age was 54.35 years with a standard deviation of 21.49. The area under curve(AUC) of CEPPIS>5 was 0.846(95%CI:0.775-0.916,P<0.01), greater than 0.713 of CPIS>6 (95%CI:0.625-0.800, P<0.01) and 0.557 of PCT>1 ng/ml(95% CI:0.463-0.652,P=0.048).Conclusions The diagnostic performance of CEPPIS is possibly better than that of CPIS and PCT, but more research is needed to investigate its diagnostic efficiency.

Key words

ventilator-associated pneumonia / echography / procalcitonin / scores / diagnostic performance

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHU Qian, DU Juan, HUANG Xiaoying, WEN Dalin, LUO Li, PENG Xiaoyu, GAN Ping, TANG Hao. Applicability of chest echography and procalcitonin pulmonary infection score(CEPPIS) in patients with ventilator-associated pneumonia(VAP)[J]. Medical Journal of the Chinese People Armed Police Forces. 2020, 31(8): 649-653

References

[1] Niederman M S,Craven D E. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171(4): 388-416.
[2] Kalanuria A A, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU[J]. Crit Care, 2014, 18(2): 208.
[3] Papazian L, Klompas M, Luyt C E. Ventilator-associated pneumonia in adults: a narrative review[J]. Intensive Care Med, 2020,46(5):888-906.
[4] Yu V L. Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw[J]. Lancet Infect Dis, 2011, 11(3): 248-252.
[5] Zagli G, Cozzolino M, Terreni A, et al. Diagnosis of ventilator-associated pneumonia: a pilot, exploratory analysis of a new score based on procalcitonin and chest echography[J]. Chest, 2014, 146(6): 1578-1585.
[6] Zhou J, Song J, Gong S, et al. Lung ultrasound combined with procalcitonin for a diagnosis of ventilator-associated pneumonia[J]. Respir Care, 2019, 64(5): 519-527.
[7] Kaziani K, Sotiriou A, Dimopoulos G. Duration of pneumonia therapy and the role of biomarkers[J]. Curr Opin Infect Dis, 2017, 30(2): 221-225.
[8] Larsson J, Itenov T S, Bestle M H. Risk prediction models for mortality in patients with ventilator-associated pneumonia: a systematic review and meta-analysis[J]. J Crit Care, 2017, 37: 112-118.
[9] Torres A, Niederman M S, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT)[J]. Eur Respir J, 2017, 50(3):117.
[10] Craven T H, Wojcik G, McCoubrey J, et al. Ventilator-associated pneumonia surveillance using two methods[J]. J Hosp Infect, 2020,6(21):518.
[11] Dominedo C, Ceccato A, Torres A. Ventilator-associated pneumonia: new principles guiding empiric antibiotic therapy[J]. Curr Opin Infect Dis, 2020, 33(2): 182-188.
[12] Isguder R, Ceylan G, Agin H, et al. New parameters for childhood ventilator associated pneumonia diagnosis[J]. Pediatr Pulmonol, 2017, 52(1): 119-128.
[13] Bouhemad B, Dransart-Raye O, Mojoli F, et al. Lung ultrasound for diagnosis and monitoring of ventilator-associated pneumonia[J]. Ann Transl Med, 2018, 6(21): 418.
[14] Chen C, Yan M, Hu C, et al. Diagnostic efficacy of serum procalcitonin, C-reactive protein concentration and clinical pulmonary infection score in Ventilator-Associated Pneumonia[J]. Med Sci (Paris), 2018, 34: 26-32.
[15] Ekren P K, Ranzani O T, Ceccato A, et al. Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society Guideline Criteria for Risk of Multidrug-Resistant Pathogens in Patients with Hospital-acquired and Ventilator-associated Pneumonia in the ICU[J]. Am J Respir Crit Care Med, 2018, 197(6): 826-830.
[16] Ju M, Hou D, Chen S, et al. Risk factors for mortality in ICU patients with Acinetobacter baumannii ventilator-associated pneumonia: impact of bacterial cytotoxicity[J]. J Thorac Dis, 2018, 10(5): 2608-2617.
[17] Luyt C E, Hekimian G, Koulenti D, et al. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia[J]. Curr Opin Crit Care, 2018, 24(5): 332-338.
[18] Mongodi S, Via G, Girard M, et al. Lung ultrasound for early diagnosis of ventilator-associated pneumonia[J]. Chest, 2016, 149(4): 969-980.
[19] Shokouhi S, Niyati R, Darazam I A, et al. Resolution of chest X-ray opacities in patients with ventilator-associated pneumonia[J]. Infect Disord Drug Targets, 2018, 18(1): 23-28.
[20] Shokri M, Ghasemian R, Bayani M, et al. Serum and alveolar procalcitonin had a weak diagnostic value for ventilator-associated pneumonia in patients with pulmonary infection score >6[J]. Rom J Intern Med, 2018, 56(1): 9-14.
[21] Wang Q, Hou D, Wang J, et al. Procalcitonin-guided antibiotic discontinuation in ventilator-associated pneumonia: a prospective observational study[J]. Infect Drug Resist, 2019, 12: 815-824.
[22] Nazerian P, Cerini G, Vanni S, et al. Diagnostic accuracy of lung ultrasonography combined with procalcitonin for the diagnosis of pneumonia: a pilot study[J]. Crit Ultrasound J, 2016, 8(1): 17.
[23] Su L X, Meng K, Zhang X, et al. Diagnosing ventilator-associated pneumonia in critically ill patients with sepsis[J]. Am J Crit Care, 2012, 21(6): e110-e119.
[24] Wongsurakiat P, Tulatamakit S. Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection[J]. Ther Adv Respir Dis, 2018, 12: 1753466618760134.